ArticleJournal of ultrasound2025
Evaluation of ultrasound derived fat fraction for metabolic associated fatty liver disease in obese patients with polycystic ovary syndrome.
Article in Journal of ultrasound, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quantitative Ultrasound for Hepatic Steatosis: A Systematic Review Highlighting the Diagnostic Performance of Ultrasound-Derived Fat Fraction.Diagnostics (Basel, Switzerland) · 2025Review
- An Exploratory Study of Serum Vasorin Levels in Polycystic Ovary Syndrome: A Novel Potential Biomarker for Diagnosis and Pathogenesis.Metabolites · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the application of ultrasound derived fat fraction (UDFF) in evaluating metabolic associated fatty liver disease in obese polycystic ovary syndrome.
methodThis study included 124 obese PCOS patients and 106 age and body mass index (BMI) matched non PCOS control group women. The two groups of data were compared to determine the prevalence of metabolic associated fatty liver disease (MAFLD) in PCOS obese patients. The 124 obese PCOS patients were divided into MAFLD group (n = 64) and non MAFLD group (n = 60). Using ROC curve analysis to evaluate the diagnostic performance of UDFF and SWV values for MAFLD. The MAFLD group was divided into mild group (n = 16), moderate group (n = 24), and severe group (n = 24). Use Spearman correlation method to analyze the relationship between UDFF value, SWV value and the severity of MAFLD.
resultMAFLD was more common in the obese PCOS group than in the control group (51.61 vs 27.36%) (χ
conclusionThe prevalence of MAFLD is significantly higher in obese PCOS patients, and UDFF technology can detect and quantitatively analyze liver fat infiltration in obese PCOS patients early. At the same time, auto-pSWE also has diagnostic significance for the progression of liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.